Fresenius Medical Care AG & Co. KGaA (FMS - Free Report) reported adjusted earnings per share (EPS) of 67 cents in the third quarter of 2019, which beat the Zacks Consensus Estimate of 59 cents by 13.6%. However, the bottom line declined 2.9% year over year.
Revenues rose 4.1% year over year to $4.91 billion and surpassed the Zacks Consensus Estimate of $4.72 billion by 4%.
In the third quarter, Fresenius Medical reported through two segments — Health Care Services and Health Care Products.
Health Care Services revenues improved 7% on a year-over-year basis and 4% at cc. The improvement came on the back of growth in same market treatments, acquisitions, and increase in dialysis days. However, the effect of sold or closed clinics and a revenue recognition adjustment for accounts receivable in legal dispute partially offset the improvement.
Health Care Products revenues climbed 16% year over year and 13% at cc. The upside was mainly driven by higher sales of home hemodialysis products, primarily as a result of the effective roll-out of the NxStage product range, dialyzers, hemodialysis solutions and concentrates. Lower volume of sales of machines partially offset the upside.
Revenues in the region grew 8% year over year and 3% at cc. On organic basis, sales in the region improved 3%.
Revenues in this region increased 10% year over year and 9% cc in the quarter. On organic basis, sales in the region improved 9%. Per management, the performance was impacted by favorable business development in Health Care Services and Health Care Products.
Revenues in this region improved 13% year over year and 9% at cc in the reported quarter. Per management, positive business development in both Health Care Services and Health Care Products led to the upside.
Revenues in Latin America rose 7% year over year and 20% at cc. Organic growth in region was 15%.
For 2019, Fresenius Medical expects adjusted revenues to grow between 3% and 7%, and adjusted net income to develop in the range of a (2%) to 2%.
For 2020, this Zacks Rank #1 (Strong Buy) company expects adjusted revenues and adjusted net income to grow at a mid to high-single digit rate.
Fresenius Medical reported strong results in the third quarter. The company continues to gain from Health Care Products and Services units, which witnessed revenue growth in the quarter under review. Revenues in the North American, EMEA and Asia-Pacific regions also improved. In fact, management remains optimistic regarding the buyouts of Sound Physicians and NxStage Medical.
Furthermore, strong view for 2019 and 2020 paints a brighter picture. Management anticipates undertaking meaningful investments in 2019 to capitalize on growth opportunities and optimize cost base.
However, Fresenius Medical faces intense competition in the field of health care services, and sale of dialysis products, which remains a woe.
Earnings of Other MedTech Majors at a Glance
Some other top-ranked stocks, which reported solid results this earning season, include Edwards Lifesciences (EW - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and ResMed Inc. (RMD - Free Report) . All three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Edwards Lifesciences delivered third-quarter 2019 adjusted EPS of $1.41, outpacing the Zacks Consensus Estimate by 15.6%. Third-quarter net sales of $1.09 billion surpassed the Zacks Consensus Estimate by 5.5%.
Thermo Fisher delivered third-quarter 2019 adjusted EPS of $2.94, which beat the Zacks Consensus Estimate by 2.1%. Revenues of $6.27 billion outpaced the Zacks Consensus Estimate by 1.3%.
ResMed reported third-quarter 2019 adjusted EPS of 93 cents, which beat the Zacks Consensus Estimate of 87 cents by 6.9%. Revenues were $681.1 million, surpassing the Zacks Consensus Estimate by 3.6%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>